Development of an Immuno-Assay by Using Survivin Antigens and Antibodies for Screening Colon Cancer Patients

• Main Authors: Wen Chun Fan, 范文君
• Other Authors: E. C. Chan
• Format: Others
• Published: 2009
• Online Access: http://ndltd.ncl.edu.tw/handle/58260833498638311195

碩士 === 長庚大學 === 醫學生物技術研究所 === 97 === In recent years, incidence and morbidity of colorectal cancer (CRC) is increasing and becoming the third leading cause of cancer death in Taiwan. Because of it’s few and unobvious symptoms, such as blood in or on the stool, pain in the abdomen and bowel habits changes, the patients usually ignore. To date, the diagnostic method for colorectal cancer, including sigmoidoscopy and colonoscopy, are too invasive for most people unwilling to take medical diagnose. Survivin, a member of inhibitor of apoptosis (IAP) family, is a caspase inhibitors. It is broadly expressed in fetal tissues, but is undetectable in the most normal adult tissue. Our purpose is to develop immunoassays by using survivin antigen and antibody for screening cancer patients. We detect the survivin protein and related antibodies response in the tissue and sera from CRC patients by Western Blot and ELISA respectively. Previously, we had detected the survivin expression and found that it is over-expressed in tumor tissues from CRC patients. Furthermore, we detected the survivin autoantibodies response in sera from CRC patients by Western Blot. The sensitivity is 65.9 % (n=205), and specificity is 82.1 % (n=140). In addition, sensitivity of anti-survivin antibodies detected by ELISA is 40.5 % (n=232), and specificity is 76 % (n=365). Combination of anti-survivin antibodies by ELISA and CEA as a multiple-marker significantly promoted the sensitivity to 64.2 %. In conclusion, we develop an efficient immunoassay for screening the CRC patients using multiple-marker of anti-survivin and CEA.